
Opinion|Videos|June 18, 2024
Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective
Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
How will the potential approval of ribociclib for early breast cancer change your treatment paradigms?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Adds a New Sunscreen to the OTC Repertoire
2
EPCORE DLBCL-1 Trial Demonstrates Durable Responses, PFS Benefit With Epcoritamab in RR LBCL
3
Gemcitabine Intravesical System: A Novel Treatment Option for BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer
4
OTC Guide: Thirty Years Strong
5
































































































































